Talmapimod Completed Phase 2 Trials for Rheumatoid Arthritis Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00089921SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate
NCT00043732Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate